Study S001326

A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects

ClinicalTrials.gov record

Registration

Registration: NCT03144271
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 58
Start: 2007-06-11
Primary completion: 2007-10-08
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: EUDRACT_NUMBER:2007-000303-15; OTHER:U1111-1193-6996

Registered primary outcomes

Number of Adverse Events [After 24-33 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.